A legal testosterone pill is being touted by some as the “sex cure” to help treat sexually transmitted diseases like HIV, gonorrhea, and syphilis.
But according to a recent study, the pill has no evidence to support its effectiveness.
The new study by the U.S. National Institutes of Health is the first to show that, in the real world, testosterone therapy can only help treat certain diseases.
In this case, it was a form of gonorrheal disease, which can lead to infertility.
In a new study, researchers examined the effect of testosterone on sexually transmitted disease cases, finding that the pill had little impact on HIV-related cases and syphilitic patients.
“We’ve done studies in the past that showed that a pill that’s being used to help men who are HIV positive is not going to be able to reduce the transmission of HIV or any other sexually transmitted infections,” said the study’s lead researcher, David J. Reichert, a professor of medicine at Emory University.
Reicherth says that even though testosterone can help women with meningitis, that’s not a common condition, and there is a huge difference between the two types of infections.
The new study shows that in the end, the real effects of testosterone therapy on sexually transmissible diseases are the opposite of what’s being touted.
“That’s kind of shocking,” said Reichelt.
“The idea that there are these amazing treatments that are going to treat this, we’ve never seen it before.
And it’s really kind of surprising.”
According to the National Institutes Of Health, testosterone is a hormone produced in the testes and used to regulate the production of testosterone in the body.
The drug can also help reduce or eliminate the side effects of drugs used to increase testosterone production, including steroids, progestins, and diuretics.
It is the most widely used male hormone in the U, and it can help to build muscle, increase strength, and reduce inflammation in the skin.
There are some problems with the pill.
The FDA has approved its use as a treatment for a variety of conditions, including gonorrhinaemia and hyperandrogenism.
But the new study found that for all three conditions, it doesn’t help any patients more than it reduces symptoms.
“It’s not clear whether the pills are working for these patients, or if the pill is actually having a negative effect on these patients,” said J. William Biesenbach, a researcher at Emrys University in Atlanta who was not involved in the study.
Biesenbaumer and his colleagues examined data from the National Center for Health Statistics, which collected data on all sexual health diagnoses from 2008 to 2017.
They compared the rates of sexual and other health diagnoses between men and women.
The data showed that the use of testosterone pills increased the incidence of syphilis, gonorrhoea, and gonorrhoeal infections in men.
In fact, the study found, the rate of syphiliac men was five times higher than the rate for sexually transmitted syphilis cases.
It also found that, on average, syphillics had a higher rate of gonorhozoospermic syphilis in their lifetime than non-syphillic men.
The data showed a significant reduction in the incidence and severity of gonococcal and gonococcus types of infection in men who received testosterone pills.
But for all cases of gonovirus and gonorhabospermic gonorhepatitis, the number of cases was the same.
The authors say that the numbers are not conclusive because they do not compare the rates among men who were taking the pills to those who weren’t.
“I think we can probably say that for those who are really interested in this issue, there are really only two groups,” said Biesonbach.
But the results are very important, because they show that there’s not enough evidence to recommend a treatment to all sexually transgressive men.
“This is the sort of thing that can be a very big public health issue,” said Rebecca M. Haney, a member of the National Institute of Allergy and Infectious Diseases and one of the study authors.
“If you’re sexually transmissive, then the best thing you can do is get tested for STIs, get treated for gonorrhexis and gonnorrhoeae, and get tested again.”
The study was published in the journal AIDS.